353 related articles for article (PubMed ID: 11571437)
1. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
[TBL] [Abstract][Full Text] [Related]
2. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
[TBL] [Abstract][Full Text] [Related]
3. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
4. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
[TBL] [Abstract][Full Text] [Related]
5. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.
Kreis H; Oberbauer R; Campistol JM; Mathew T; Daloze P; Schena FP; Burke JT; Brault Y; Gioud-Paquet M; Scarola JA; Neylan JF;
J Am Soc Nephrol; 2004 Mar; 15(3):809-17. PubMed ID: 14978184
[TBL] [Abstract][Full Text] [Related]
6. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
[TBL] [Abstract][Full Text] [Related]
7. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.
Mota A; Arias M; Taskinen EI; Paavonen T; Brault Y; Legendre C; Claesson K; Castagneto M; Campistol JM; Hutchison B; Burke JT; Yilmaz S; Häyry P; Neylan JF;
Am J Transplant; 2004 Jun; 4(6):953-61. PubMed ID: 15147430
[TBL] [Abstract][Full Text] [Related]
9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
10. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
11. Can we eliminate both calcineurin inhibitors and steroids?
Lebranchu Y
Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J
Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950
[TBL] [Abstract][Full Text] [Related]
15. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
[TBL] [Abstract][Full Text] [Related]
17. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
Friend P; Russ G; Oberbauer R; Murgia MG; Tufveson G; Chapman J; Blancho G; Mota A; Grandaliano G; Campistol JM; Brault Y; Burke JT;
Transpl Int; 2007 Sep; 20(9):754-60. PubMed ID: 17565578
[TBL] [Abstract][Full Text] [Related]
18. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
19. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
20. New approaches to de novo immunosuppression and steroid elimination.
Lebranchu Y
Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
